Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Brain Metastases represent the most common intracranial tumors in adults, occurring in approximately 10-40% of patients with advanced solid cancers and contributing substantially to cancer-related morbidity and mortality. The growing incidence, driven by improved cancer survival and enhanced diagnostic imaging, continues to expand the need for innovative therapies. Brain metastases pipeline analysis by Expert Market Research highlights a diverse portfolio of investigational candidates focused on targeted therapies, novel drug delivery platforms, and precision medicine approaches to improve intracranial disease management and patient outcomes.

  • Major companies involved in the brain metastases pipeline analysis include GT Medical Technologies, Inc., Allist Pharmaceuticals, Inc., and others.

  • Leading drugs currently in the pipeline include 186RNL, AO-252, and others.

  • The brain metastases pipeline is driven by advances in blood-brain barrier-penetrant therapeutics, targeted radiopharmaceuticals, intracranial drug delivery technologies, and biomarker-guided precision oncology. Increasing integration of stereotactic radiation with systemic therapies and the development of HER2- and EGFR-directed agents are accelerating innovation and expanding treatment opportunities for patients with metastatic brain tumors.

Report Coverage

The Brain Metastases Pipeline Analysis Report by Expert Market Research gives comprehensive insights into brain metastases therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for brain metastases. The brain metastases report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The brain metastases pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with brain metastases treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to brain metastases.

Brain Metastases Pipeline Analysis by Drug Class

Read more about this report - Request a Free Sample

Brain Metastases Pipeline Outlook

The brain metastases pipeline continues to expand with increasing emphasis on therapies targeting intracranial malignancies and overcoming the challenges of the blood-brain barrier. In August 2025, the U.S. FDA granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients with H3 K27M-mutant diffuse midline glioma following prior therapy. Although approved for diffuse midline glioma, this milestone reinforces confidence in neuro-oncology drug development and is expected to stimulate innovation in investigational therapies addressing brain metastases.

Brain Metastases Epidemiology

Brain Metastases are the most common intracranial tumors in adults, occurring in approximately 10-40% of patients with advanced solid malignancies and accounting for an estimated 200,000-400,000 new cases annually in the United States. Lung cancer, breast cancer, and melanoma remain the leading primary tumors associated with brain metastases. The incidence continues to increase due to improved systemic cancer survival and greater use of advanced neuroimaging, enabling earlier detection and intervention for metastatic brain disease.

Brain Metastases – Pipeline Therapeutic Assessment

This section of the report covers the analysis of brain metastases drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

The brain metastases pipeline analysis report covers 50+ drug analyses based on drug classes:

  • Small Molecules
  • Monoclonal Antibodies
  • Cell Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

  • Oral
  • Parenteral
  • Others

Brain Metastases Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total brain metastases clinical trials. Early Phase I (3.02%), Phase I (21.12%), Phase II (58.19%), Phase III (15.52%), reflecting the distribution of drug candidates across the different stages of clinical development.

Brain Metastases Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the brain metastases pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The brain metastases report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for brain metastases. In August 2024, the U.S. FDA approved vorasidenib (Voranigo) for adults and children aged 12 years and older with Grade 2 IDH1/IDH2-mutant astrocytoma or oligodendroglioma following surgery.

Brain Metastases Clinical Trials – Key Players

The EMR report for the brain metastases pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed brain metastases therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in brain metastases clinical trials:

  • GT Medical Technologies, Inc.
  • Allist Pharmaceuticals, Inc.
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Essen Biotech
  • Biostar Pharma, Inc.
  • A2A Pharmaceuticals Inc.
  • Stemline Therapeutics, Inc.
  • Neonc Technologies, Inc.
  • Lexeo Therapeutics
  • AstraZeneca
  • Iambic Therapeutics, Inc.
  • Wayshine Biopharm, Inc.

Brain Metastases – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for brain metastases. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of brain metastases drug candidates.

Drug: SHR-A1811

SHR-A1811 is an antibody-drug conjugate (ADC) developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. It combines a HER2-targeting monoclonal antibody with a cytotoxic payload to selectively eliminate HER2-expressing tumor cells associated with brain metastases, while minimizing damage to healthy tissues. The ongoing clinical study is expected to be completed in 2028. Hengrui Pharmaceuticals is a leading global biopharmaceutical company with a strong oncology pipeline focused on innovative biologics, ADCs, and targeted therapies for solid tumors.

Drug: 186RNL

186RNL is a radiopharmaceutical developed by Plus Therapeutics, Inc. for patients with brain metastases. The investigational therapy delivers the beta-emitting radioisotope rhenium-186 directly into intracranial tumors through convection-enhanced delivery, enabling localized radiation while reducing systemic exposure. The clinical program is expected to be completed in 2027. Plus Therapeutics is a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers and other difficult-to-treat malignancies.

Drug: DSB2455

DSB2455 is an antibody-drug conjugate (ADC) being developed by Duality Biologics for the treatment of brain metastases. The therapy is designed to selectively bind tumor-associated targets and deliver a potent cytotoxic agent directly into cancer cells, improving antitumor activity while limiting systemic toxicity. The ongoing clinical study is expected to be completed in 2028. Duality Biologics is a biotechnology company dedicated to advancing next-generation ADC platforms for oncology indications with significant unmet medical needs.

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Key Questions Answered in the Brain Metastases Pipeline Insight Report

  • Which companies/institutions are leading the brain metastases drug development?
  • Which company is leading the brain metastases pipeline development activities?
  • What is the current brain metastases commercial assessment?
  • What are the opportunities and challenges present in the brain metastases pipeline landscape?
  • What is the efficacy and safety profile of brain metastases pipeline drugs?
  • Which company is conducting major trials for brain metastases drugs?
  • Which companies/institutions are involved in brain metastases collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in brain metastases?

Reasons To Buy This Report

The Brain Metastases Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for brain metastases. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into brain metastases collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Glioblastoma Multiforme Treatment Market

Recurrent Glioblastoma Pipeline Analysis Report

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Small Molecules
  • Monoclonal Antibodies
  • Cell Therapies

Leading Sponsors Covered

  • GT Medical Technologies, Inc.
  • Allist Pharmaceuticals, Inc.
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Essen Biotech
  • Biostar Pharma, Inc.
  • A2A Pharmaceuticals Inc.
  • Stemline Therapeutics, Inc.
  • Neonc Technologies, Inc.
  • Lexeo Therapeutics
  • AstraZeneca
  • Iambic Therapeutics, Inc.
  • Wayshine Biopharm, Inc.

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us